O-(2-18F-ﬂuoroethyl)-L-tyrosine (18F-FET) PET as a potential selection tool for second surgery in glioblastoma patients.

IF 1.3 4区医学 Q4 CLINICAL NEUROLOGY

Journal of neurosurgical sciences Pub Date : 2023-12-21 DOI:10.23736/S0390-5616.23.06019-8

Orazio S Santonocito, Gianluca Grimod, Anna L DI Stefano, Francesco Pieri, Mariagrazia Nizzola, Nicola Mazzuca, Francesco Pasqualetti, Riccardo Morganti, Vanna Zucchi, Carlo Gambacciani

{"title":"O-(2-18F-ﬂuoroethyl)-L-tyrosine (18F-FET) PET as a potential selection tool for second surgery in glioblastoma patients.","authors":"Orazio S Santonocito, Gianluca Grimod, Anna L DI Stefano, Francesco Pieri, Mariagrazia Nizzola, Nicola Mazzuca, Francesco Pasqualetti, Riccardo Morganti, Vanna Zucchi, Carlo Gambacciani","doi":"10.23736/S0390-5616.23.06019-8","DOIUrl":null,"url":null,"abstract":"Background: Treatment-related changes still represent a diagnostic challenge in the management of patients with suspect of recurrent glioblastoma. The specificity of conventional MRI in detecting recurrence remains limited. Brain PET imaging provides information on tumor metabolism and can contribute to improving the diagnostic accuracy of cerebral neoplasms. We performed a retrospective analysis to evaluate the clinical value of O-(2-18F-ﬂuoroethyl)-L-tyrosine (18F-FET) PET in the diagnosis of glioblastoma recurrence.Methods: A retrospective analysis on patients considered suitable for salvage surgery for recurrence glioblastoma was performed. 18F-FET-PET was performed to investigate gadolinium enhancement suspected for recurrence. Static and kinetic 18F-FET parameters were analyzed and related to O-6-methylguanine-DNA methyltransferase (MGMT) status.Results: Forty-two of the 51 patients who underwent 18F-FET-PET were re-operated. In each case, neuropathological diagnosis of tumor recurrence was confirmed. pMGMT hypermethylation was detected in 21 patients. Mean tumor-to-brain ratios (TBR) max was 3.87 (range 2.6-6.0). Static and kinetic 18F-FET parameters were similar according to MGMT status.Conclusions: 18FET-PET can be a reliable tool to improve the selection of patients suitable for salvage surgery for glioblastoma recurrence.","PeriodicalId":16504,"journal":{"name":"Journal of neurosurgical sciences","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurosurgical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0390-5616.23.06019-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment-related changes still represent a diagnostic challenge in the management of patients with suspect of recurrent glioblastoma. The specificity of conventional MRI in detecting recurrence remains limited. Brain PET imaging provides information on tumor metabolism and can contribute to improving the diagnostic accuracy of cerebral neoplasms. We performed a retrospective analysis to evaluate the clinical value of O-(2-¹⁸F-ﬂuoroethyl)-L-tyrosine (¹⁸F-FET) PET in the diagnosis of glioblastoma recurrence.

Methods: A retrospective analysis on patients considered suitable for salvage surgery for recurrence glioblastoma was performed. ¹⁸F-FET-PET was performed to investigate gadolinium enhancement suspected for recurrence. Static and kinetic ¹⁸F-FET parameters were analyzed and related to O-6-methylguanine-DNA methyltransferase (MGMT) status.

Results: Forty-two of the 51 patients who underwent ¹⁸F-FET-PET were re-operated. In each case, neuropathological diagnosis of tumor recurrence was confirmed. pMGMT hypermethylation was detected in 21 patients. Mean tumor-to-brain ratios (TBR) max was 3.87 (range 2.6-6.0). Static and kinetic ¹⁸F-FET parameters were similar according to MGMT status.

Conclusions: ¹⁸FET-PET can be a reliable tool to improve the selection of patients suitable for salvage surgery for glioblastoma recurrence.

查看原文本刊更多论文

O-(2-18F-氟乙基)-L-酪氨酸（18F-FET）PET作为胶质母细胞瘤患者二次手术的潜在选择工具。

背景：治疗相关的变化仍是疑似复发性胶质母细胞瘤患者治疗过程中的诊断难题。传统磁共振成像在检测复发方面的特异性仍然有限。脑 PET 成像可提供肿瘤代谢信息，有助于提高脑肿瘤诊断的准确性。我们进行了一项回顾性分析，评估O-(2-18F-氟乙基)-L-酪氨酸（18F-FET）PET在胶质母细胞瘤复发诊断中的临床价值：对被认为适合接受复发胶质母细胞瘤挽救手术的患者进行回顾性分析。进行18F-FET-PET检查是为了调查疑似复发的钆增强情况。分析了18F-FET的静态和动力学参数，并将其与O-6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）状态联系起来：结果：51 例接受 18F-FET-PET 的患者中有 42 例接受了再次手术。其中 21 例患者检测到 pMGMT 高甲基化。肿瘤与脑的平均比值（TBR）最大值为 3.87（范围为 2.6-6.0）。静态和动力学18F-FET参数与MGMT状态相似：18FET-PET是一种可靠的工具，可用于选择适合接受胶质母细胞瘤复发挽救手术的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neurosurgical sciences CLINICAL NEUROLOGY-SURGERY

CiteScore

3.00

自引率

5.30%

发文量

202

审稿时长

>12 weeks

期刊介绍： The Journal of Neurosurgical Sciences publishes scientific papers on neurosurgery and related subjects (electroencephalography, neurophysiology, neurochemistry, neuropathology, stereotaxy, neuroanatomy, neuroradiology, etc.). Manuscripts may be submitted in the form of ditorials, original articles, review articles, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work.